Autolus Therapeutics plc (AUTL) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Autolus Therapeutics plc
Address
The MediaWorks
London, GL W12 7FP
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 20 3829 6230
Website
Sector
Healthcare
Industry
Biotechnology
Employees
647
First IPO Date
June 22, 2018
Key Executives
| Name | Title | Pay | Year Born |
| Christian Martin Itin | Chief Executive Officer & Director | 2.68M | 1964 |
| Chris Williams | Senior VP & Chief Business Development Officer | 0 | 1980 |
| Martin Pule MBBS | Founder, Senior Vice President & Chief Scientific Officer | 0 | 1972 |
| Matthias Will | Senior Vice President & Chief Development Officer | 0 | 1973 |
| Alexander Swan | Senior Vice President & Chief Human Resources Officer | 0 | 1965 |
| Alex Driggs | Senior Vice President of Legal Affairs & General Counsel and Secretary | 0 | 1976 |
| Christopher Vann | Senior Vice President & Chief Operating Officer | 0 | 1965 |
| Patrick McIlvenny | Senior VP of Finance, Chief Accounting Officer & Principal Accounting Officer | 0 | 1980 |
| Robert F. Dolski | Senior Vice President & Chief Financial Officer | 0 | 1971 |
| Miranda Neville | Senior VP & Chief Technology Officer | 0 | 1975 |
Description
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
